Research and Development                                                 (64.4)  (34.2)   (88%) (138.2)   (86.6)   (60%) 
Selling                                                                  (32.4)  (32.9)    (2%)  (89.0)   (75.0)   (19%) 
General and Administrative                                               (19.4)  (13.3)   (46%)  (60.1)   (37.2)   (62%) 
Operating Profit / (Loss)                                                (82.4)  (62.0)   (33%) (183.3)     93.1       > 
                                                                                                                  (100%) 
Other Income                                                                2.0     1.7   (18%)     4.8     11.6   (59%) 
Other Expenses                                                            (1.2)   (1.3)    (8%)   (4.6)    (2.9)     59% 
Finance Income                                                           (17.0)    32.4       >    99.3     60.5     64% 
                                                                                         (100%) 
Finance Expenses                                                         (55.7)  (67.6)     18%  (92.4)  (101.9)    (9%) 
Income from Reversals of Impairment Losses / (Impairment Losses) on 
Financial Assets                                                            0.3   (0.4)   >100%     0.6    (1.1)   >100% 
Income Tax Benefit / (Expenses)                                            41.2    31.9   (29%)    42.2     55.2   (24%) 
Consolidated Net Profit (+) / (Loss)                                    (112.8)  (65.3)   (73%) (133.5)    114.4  > 100% 
Earnings per Share, Basic and Diluted (in EUR)                             (3.30)  (2.00)   (65%)  (4.03)        -       - 
Earnings per Share, Basic (in EUR)                                              -       -       -       -     3.53       - 
Earnings per Share, diluted (in EUR)                                            -       -       -       -     3.51       - 
Cash and investments (end of period)                                    1,130.9 1,061.8      7% 1,130.9 1,244.0*    (9%)

*Value as of December 31, 2020

MorphoSys will hold its conference call and webcast tomorrow, November 11, 2021, to present the results for the third quarter and first nine months of 2021 and the further outlook for 2021.

Dial-in number for the conference call (in English) at 2:00pm CET; 1:00pm GMT; 8:00am EST: Germany: +49 69 201 744 220 For UK residents: +44 203 009 2470 For US residents: +1 877 423 0830 (All numbers reachable from any geography) Participant PIN: 55329657# Please dial in 10 minutes before the beginning of the conference.

A live webcast and slides will be made available at the Investors section under "Presentations and Conferences" on MorphoSys' website at http://www.morphosys.com and after the call, a slide-synchronized audio replay of the conference will be available at the same location.

The statement for the third quarter/first nine months of 2021 (IFRS) is available online: http://www.morphosys.com/Reports

About Monjuvi^(R) (tafasitamab) Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb^ (R) engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). In the United States, Monjuvi^(R) (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In Europe, Minjuvi^(R) (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.

Minjuvi^(R) and Monjuvi^(R) are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi^(R) in the U.S., and marketed by Incyte under the brand name Minjuvi^(R) in the EU.

XmAb^(R) is a registered trademark of Xencor, Inc. About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. In 2017, Tremfya^(R) (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys Group, including the fully owned U.S. subsidiaries MorphoSys US Inc. and Constellation Pharmaceuticals, Inc., has more than 750 employees. For more information visit www.morphosys.com or www.morphosys-us.com.

Minjuvi^(R) and Monjuvi^(R) are registered trademarks of MorphoSys AG. Tremfya^(R) is a registered trademark of Janssen Biotech, Inc. MorphoSys Forward-Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys' expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact: 


 
Media Contacts:                Investor Contacts: 
Thomas Biegi                   Dr. Julia Neugebauer 
Vice President                 Senior Director 
Tel.: +49 (0)89 / 899 27 26079 Tel: +49 (0)89 / 899 27 179 
thomas.biegi@morphosys.com     julia.neugebauer@morphosys.com 
 
Jeanette Bressi                Myles Clouston 
Director, US Communications    Senior Director 
Tel: +1 617 404 7816           Tel: +1 857 772 0240 
jeanette.bressi@morphosys.com  myles.clouston@morphosys.com

-----------------------------------------------------------------------------------------------------------------------

2021-11-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      MorphoSys AG 
              Semmelweisstr. 7 
              82152 Planegg 
              Germany 
Phone:        +49 (0)89 899 27-0 
Fax:          +49 (0)89 899 27-222 
E-mail:       investors@morphosys.com 
Internet:     www.morphosys.com 
ISIN:         DE0006632003 
WKN:          663200 
Indices:      SDAX, TecDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq 
EQS News ID:  1248080 
 
End of News   DGAP News Service 
=------------

1248080 2021-11-10

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1248080&application_name=news

(END) Dow Jones Newswires

November 10, 2021 16:01 ET (21:01 GMT)